Real-time Identification of the Aberrant Left Hepatic Arterial Territory in the Liver Using Near-infrared Fluorescence Imaging
NCT ID: NCT05971069
Last Updated: 2023-08-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2021-12-17
2023-06-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There has been no standardized method to evaluate the ALHA, and to decide whether preserve or ligate it.
This prospective study has been designed to develop the decision algorithm to define the ALHA preservation/ligation, using near-infrared fluorescence imaging during surgery. "
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Using Infrared Spectroscopy for Diagnosis Severity of Nonalcoholic Fatty Liver Disease
NCT02860884
Ga-68 Dolacga PET Scan in HCC Under RFA
NCT06792097
Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT
NCT02985034
A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
NCT03313648
A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma
NCT02482909
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group1
Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
Group1
Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
Group2
Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Group2
Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Group3
No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Group3
No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group1
Entire fluorescence defect on the Lt. lobe of liver → Preservation of the aberrant left hepatic artery
Group2
Partial fluorecence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Group3
No fluorescence defect on the Lt. lobe of liver → Ligation of the aberrant left hepatic artery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients aged between 20 to 80
3. Patients with an ECOG 0 or 1
4. Patients who were confirmed the presence of aberrant left hepatic artery before or during surgery
Exclusion Criteria
2. Patients who diagnosed liver cirrhosis or infectious liver disease
3. Patients who underwent liver resection, or chemotherapy for gastric cancer
4. Patients planned for combined liver resection or cholecystectomy during gastrectomy
20 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gangnam Severance Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
In Gyu Kwon
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GangnamSeverance Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3-2021-0376
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.